학술논문

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 1 September 2023, 29(17):3352-3361)
Subject
Language
English
ISSN
15573265
10780432